Department of Respiratory Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Department of Respiratory Medicine, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
Pulm Pharmacol Ther. 2019 Feb;54:39-52. doi: 10.1016/j.pupt.2018.11.007. Epub 2018 Nov 26.
Over the years, mesenchymal stromal (stem) cells (MSCs) have been pre-clinically applied in the treatment of variety kinds of diseases including asthma and chronic lung diseases. Aim of the current study was to systematically review and to conduct meta-analysis on the published studies of MSC treatment in asthma animal models.
Publications on the MSC and asthma treatment was thoroughly searched in the electronic databases. Statistical analysis was then performed using the Comprehensive Meta-Analysis software (Version 3). Effect of MSC therapy on asthma model was assessed by Hedges's g with 95% confidence intervals (95% CIs). Random effect model was used due to the heterogeneity between the studies.
Meta-analysis of the 32 included studies showed that MSC transplantation was significantly in favor of attenuating lung injury and remodeling (Hedges's g = -9.104 ± 0.951 with 95% CI: -10.969 ∼ -7.240, P < 0.001) and airway inflammation (Hedges's g = -4.146 ± 0.688 with 95% CI: -5.495 ∼ -2.797, P < 0.001). The mechanism of MSC therapy in asthma seems to be regulating the balance of Th1 cytokine and Th2 cytokines (IFN-γ: Hedges's g = 4.779 ± 1.408 with 95% CI: 1.099-2.725, P < 0.001; IL-4: Hedges's g = -10.781 ± 1.062 with 95% CI: -12.863 ∼ -8.699, P < 0.001; IL-5: Hedges's g = -10.537 ± 1.269 with 95% CI: -13.025 ∼ -8.050, P < 0.001; IL-13: Hedges's g = -6.773 ± 0.788 with 95% CI: -8.318 ∼ -5.229, P < 0.001).
Findings of the current systemic review suggested a potential role for MSCs in asthma treatment although it is still challenging in clinical practice. The mechanisms of MSCs in pre-clinical asthma treatment may be associated with attenuating airway inflammation through regulating Th1 and Th2 cytokines.
多年来，间充质基质（干）细胞（MSCs）已在临床前应用于治疗各种疾病，包括哮喘和慢性肺部疾病。本研究的目的是系统地回顾和对哮喘动物模型中 MSC 治疗的已发表研究进行荟萃分析。
在电子数据库中彻底搜索关于 MSC 和哮喘治疗的出版物。然后使用 Comprehensive Meta-Analysis 软件（版本 3）进行统计分析。使用 95%置信区间（95%CI）的 Hedges'g 评估 MSC 治疗对哮喘模型的影响。由于研究之间存在异质性，因此使用了随机效应模型。
对 32 项纳入研究的荟萃分析表明，MSC 移植显著有利于减轻肺损伤和重塑（Hedges'g =-9.104±0.951，95%CI：-10.969～-7.240，P<0.001）和气道炎症（Hedges'g =-4.146±0.688，95%CI：-5.495～-2.797，P<0.001）。MSC 治疗哮喘的机制似乎是调节 Th1 细胞因子和 Th2 细胞因子的平衡（IFN-γ：Hedges'g =4.779±1.408，95%CI：1.099-2.725，P<0.001；IL-4：Hedges'g =-10.781±1.062，95%CI：-12.863～-8.699，P<0.001；IL-5：Hedges'g =-10.537±1.269，95%CI：-13.025～-8.050，P<0.001；IL-13：Hedges'g =-6.773±0.788，95%CI：-8.318～-5.229，P<0.001）。
尽管在临床实践中仍然具有挑战性，但当前系统评价的研究结果表明 MSC 在哮喘治疗中具有潜在作用。MSC 在临床前哮喘治疗中的作用机制可能与通过调节 Th1 和 Th2 细胞因子减轻气道炎症有关。
